Conrig Pharma develops drugs with attractive safety and efficacy profiles to provide new treatments of serious illnesses. Initial focus will be on development of ST-015 for treatment of serious respiratory disorders . ST-015 could enter Phase IIa clinical studies in late 2018.
| Website | http://www.conrigpharma.com |
| Revenue | $5 million |
| Employees | View employees |
| Founded | 2010 |
| Address | 3 Ole Maaløes Vej, København N, Capital Region 2200, DK |
| Industry | Biotechnology, Drug Manufacturing & Research, Drug Discovery, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Pharmaceutical |
| Competitors | Pfizer, Johnson & Johnson, Novartis, Merck & Co., Inc., Roche, AstraZeneca, GSK, Sanofi, AbbVie, Regeneron +43 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Conrig Pharma employee's phone or email?
Conrig Pharma Questions
The Conrig Pharma annual revenue was $5 million in 2026.
Conrig Pharma is based in København N, Capital Region.
The NAICS codes for Conrig Pharma are [32541, 3254, 325, 32].
The SIC codes for Conrig Pharma are [283, 28].
G2Crowd Trusted
300K+
Plugin Users
